Genomic organization of a human cystine transporter gene (SLC3AI) and identification of novel mutations causing cystinuria. Cystinuria is a common inherited aminoaciduria that leads to recurrent cystine nephrolithiasis. Mutations in a gene encoding a renal amino acid transporter (SLC3AI) have been identified in patients with cystinuria establishing one molecular cause for the disease. To facilitate systematic screening of this gene for mutations, we have delineated the complete genomic organization of the SLC3AJ coding region using polymerase chain reaction strategies. The complete coding region of the gene is contained within a single yeast artificial chromosome clone and consists of 10 exons and 9 introns. Oligonucleotide primers capable of amplifying selected exons have been made and used in mutational analysis of DNA from 24 cystinuria probands. We illustrate the usefulness of this approach by identifying two novel SLC3AJ mutations. One novel mutation causes replacement of a highly conserved arginine residue (arginine-452) with tryptophan in the cytoplasmic loop between the putative third and fourth membrane spanning segments. A second previously unreported mutation results in replacement of a highly conserved tyrosine (tyrosine-461) residue with histidine in the same region of the protein. In addition, we detected three previously reported SLC3AI mutations, R270X, 1500 +1/G toT, and M467T, the latter being present in -20% of cystinuria chromosomes examined. Our findings provide a foundation for the development of more accessible diagnostic screening assays for detecting SLC3AI mutations using patient genomic DNA, and also contribute to the emerging spectrum of cystinuria genotypes.
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Cystinuria is an autosomal recessive disorder that leads to recurrent nephrolithiasis. The disease is caused by an inherited defect in the transport of cystine and dibasic amino acids (arginine, lysine, ornithine) across the apical membranes of proximal renal tubular and jejunal epithelial cells and has an incidence of between 1:7000 and 1:12000 [1] . Cystine is poorly soluble in urine and its precipitation results in the formation of stones. Recurrent cystine nephrolithiasis occurs throughout the patient's lifetime and is often associated with significant morbidity.
A candidate gene for cystinuria was identified recently by three groups using expression cloning strategies in Xenopus oocytes [2- 41. The -680 amino acid protein (designated as D2, or rBAT) encoded by this gene exhibits Na independent transport of cystine and dibasic amino acids when expressed in oocytes [2-41, and is localized to the microvilli of the S3 segment of proximal tubule [5] . Human cystine transporter eDNA sequences were reported subsequently [6, 7] , and the corresponding gene (designated as SLG3AJ) has been assigned to human chromosome 2 (2p2l) [8, 91 • This chromosomal localization correlated well with that determined by linkage analysis in cystinuria pedigrees [10] .
Direct demonstration of SLC3AI mutations was first reported in 1994 by Calonge et al [11] , thus confirming its role as a cystinuria gene. Several additional mutations have been found in SLC3AJ which co-segregate with the cystinuria phenotype [12] [13] [14] . Functional characterizations of certain missense mutations have revealed reduced transporter activity consistent with the physiologic defect that exists in the disease [ii, 12] . In many cases, the detection of SLC3AJ mutations has relied upon illegitimate transcription of mRNA from this gene in lymphoblastoid cell lines established from peripheral blood leukocytes of cystinuric patients [11] [12] [13] [14] . This is a time consuming and labor intensive process which requires an initial delay of several weeks for establishment of the lymphoblastoid lines. Furthermore, this approach is not optimal for delineating mutations affecting critical splice junction sequences. Additional mutations have been found using information regarding the partial genomic organization of the gene [13] [14] [15] .
To facilitate the ascertainment of SLC3AJ mutant genotypes, we have defined the complete genomic organization of the SLC3A1 coding region, and developed exon-specific oligonucleotide primers for use in mutational analysis. We further demonstrate the utility of this approach by identifying five mutant alleles including two novel missense mutations. This information will facilitate the identification of other SLC3A I mutations, contribute to our understanding of the molecular basis of cystinuria, and provide the foundation for genotype-phenotype correlations. pairs to amplify SLC3AJ segments from genomic DNA using the polymerase chain reaction (PCR). Reactions using primer pairs Bf181 7/Br1964 (C-terminus; Bfl 817: 5 '-AATClTFATCGTGGT-TCTGA-3'; BrI 964: 5 '-TGAGTCCCTCTCCCTTGTCC-3') and Bf13/Br322 (N-terminus; Bf13: 5'-'TTATGTCYT'CGGAGTGC-CTTC-3'; Br322: 5'-CACCAGCACAGAAGCCACTG-3') were both successful in amplifying 166 bp (nucleotides 13 to 341) and 329 bp (nucleotides 1817-1982) products, respectively, from human genomic DNA that were co-linear with the human D2 eDNA as determined by direct sequencing. The Bf1817/Br1964 primer set was then used to screen the CEPH megaYAC human genomic library (provided in microtiter well format by Research Genetics, Huntsville, AL, USA). Reactions were performed using 35 cycles of 94°C one minute, 48°C one minute, and 72°C one minute, and a final MgC12 concentration of 2 m. Three positive clones were identified. Yeast DNA was isolated from 10 ml liquid cultures by the method of Hoffman and Winston [16] and re-screened for the presence of SLC3AI sequences using the Bf1817/Brl 964 primer set. Two clones were shown to be false positives. Clone yhCEPH888G9 was positive and was used for delineation of genomic organization.
Definition of SLC3AJ intron-exon boundaries To screen for intron-exon boundaries, we initially employed vectorette PCR [17] . Yeast DNA isolated from clone yhCEPH888G9 was digested with one of three restriction enzymes AluI, RsaI, or Hinfl), and the resulting restriction fragments were then ligated to specialized double stranded DNA linkers (vectorettes) as described [17] . The resulting vectorette libraries were then used as templates in PCR reactions consisting of an SLC3AJ coding sequence primer paired with a vectorette specific primer. Single band products obtained in these PCR reactions were directly sequenced after spin column purification (Qiagen, Corp). In the case of multiple products, Southern blot hybridization with a nested [32P] end-labeled oligonucleotide probe was performed. Positively hybridizing products were gel purified, suhcloned into the pCRII plasmid vector, verified by colony hybridization, and then sequenced.
To define intron-exon boundaries not fully discerned with vectorette PCR, we utilized either intron-bridging PCR or inverse PCR [18] . For the latter, YAC DNA was digested with one of three restriction enzymes (Sau3AI, HhaI, or TaqI) and the resulting fragments were self-ligated under conditions that favored circularization. PCR primers designed to extend outward in both directions from a known sequence were employed to create products bridging the ligated ends. Products of inverse PCR reactions were processed identically to those of vectorette reactions.
Splice sites were located by identifying consensus splice junction sequences at points of divergence between the eDNA and PCR-generated genomic sequence using computer alignments. For each exon, an overlapping sequence in both directions was obtained. Splice junctions were sequenced in both directions.
Single-strand conformational analysis (SSCA) Twenty-four blood samples were obtained from patients with well-documented cystinuria as defined by a history of recurrent renal stones and elevated urine cystine level. In most cases, we were unable to assign the allelie type of cystinuria because of the lack of urinary cystine excretion data on related heterozygous carriers. Genomic DNA was isolated by a standard phenol-based method [19] , Exon-specific oligonucleotide primers were designed based upon genomic sequence data, and tested by PCR amplification of human DNA to confirm the expected product size (Table 1) .
For SSCA, genomic DNA samples were amplified by PCR (8 mm at 94°C, followed by 30 cycles of 94°C for 1 mm, annealing temperature for 1.5 mm, and 72°C for 1. Baker, Inc.). Gels were electrophorcsed 14 hours at 8 watts constant power in Tris-borate-EDTA buffer. After electrophoresis, gels were transferred to blotting paper, dried, and subjected to autoradiography.
Nucleotide sequence determination Direct sequencing of PCR products was performed using the sequencing method (Applied Biosystems, Inc.). Sequencing reac-DNA allowed to elute overnight at room temperature. Ten tions were electrophoresed and detected on an Applied Biosys-microliters of eluted DNA were re-amplified using the original tems model 377 automated sequencer. For sequencing of abnor-primers, and the resulting products were purified by spin column mal SSCA conformers, individual bands were carefully excised chromatography (Qiagen) before cycle sequencing. Sequence from dried gels, placed into 100 .d of deionized water, and the variants were confirmed by sequencing the complementary strand. Allele-specific oligonucleotide hybridization An oligonucleotide probe (5 '-ACAGTTCATGGCTGACT-3') was synthesized to match the sequence of the R452W allele. Genomic DNAs (200 ng) from affected individuals with the R452W allele and 97 normal controls were amplified using the exon 8 primer pair, and 10 p1 of each product were alkali denatured (0.4 M NaOH/25 mivi EDTA), then applied to nylon membranes (Hybond-N, Amersham Corp.) using a slot-blot apparatus (Schleicher and Schuell). Membranes were heat and UV fixed then prehybridized for one hour in 5 X SSPE, 5x Denhardt's solution, and 1% SDS. The allele-specific probe was end-labeled using T4 polynucleotide kinase in the presence of
[32P]-y-ATP. Unincorporated nucleotides were removed by G- 25 Sephadex spin column chromatography. Hybridizations were done at 48°C for four hours with 0.3 to 0.6 x 106 cpm/ml of the end-labeled probe. Filters were washed three times with I x SSPE/0.1% SDS for 20 minutes at the hybridization temperature, and subjected to autoradiography.
Results

Genomic cloning of SLC3AJ
Without prior knowledge regarding the size of the SLC3AJ gene, we elected to use a reference human genomic library constructed in yeast artificial chromosomes (CEPH Mega-YAC library) capable of carrying up to I megabase inserts. We used a PCR-based screening strategy employing a primer pair designed to amplify a 166 bp product corresponding to part of the carboxyl-terminus of SLC3AJ from human genomic DNA. This strategy permitted isolation of a single YAC clone (yhCEPH888G9, 940 kb) that contains the gene. This clone contained the complete SLC3AI coding region as demonstrated by successfully amplifying sequences from the extreme regions of both the amino-and carboxyl termini.
Definition of intron-exon boundaries
To define splice junctions in SLC3AJ, we initially employed vectorette PCR using an ordered set of oligonucleotide primers designed to anneal at 150 to 200 bp intervals along the coding sequence of the gene on both strands. Vectorette PCR was originally developed to aid in the isolation of end-sequences in YAC DNA [17] , but has been used successfully to delineate intron-exon boundaries in complex human genes [20, 21] . Approximately two thirds of the SLC3A1 coding sequence was isolated using this approach, and nearly all of the splice junctions were identified on at least one intron-exon boundary. To obtain the remaining splice junction sequences, we used either direct intronspanning PCR or inverse PCR. Use of all three techniques yielded information about the complete intron-exon organization of the SLC3AJ coding region without the need for high resolution restriction mapping or the subcloning of the YAC clone. The gene consists of ten exons, ranging in size from 116 to 474 base pairs. The first and last exons are the largest, approximately four times larger than the intervening exons, which are all between 100 and 200 base pairs in size (Fig. 1A) . The first exon containing coding sequence was designated as exon 1, and analysis of adjacent 5' flanking sequence revealed a high degree of nucleotide sequence identity with the proximal promoter region of the rat SLC3AJ homologue [221 including an experimentally determined transcription start site and TATA box motif (Fig. 1B) .
In human SLC3AI, introns interrupt the reading frame twice (introns I and 6). The splice junction sequences are provided in Table 2 . All intron-exon boundaries conform closely to the consensus pattern observed in eukaryotic genes [23] ; all introns begin with the canonical GT dinucleotide and terminate in an AG dinucleotide. The genomic sequence of SLC3AJ was co-linear with the human D2 eDNA sequence except a previously reported difference in codon 446 (GGA vs. GGT), which does not affect the amino acid sequence, and is a likely polymorphism.
Identification of SLC3AJ mutations
We used the genomic sequence information described above to design oligonucleotide primers to facilitate PCR amplification of individual exons from genomic DNA for single-strand conformational analysis (SSCA). Exons 2 to 9 could be amplified using single pairs of intronic primers, but exons 1 and 10 each required amplification of two overlapping regions to restrict the product size to a range (150 to 250 bp) that provides for optimal SSCA sensitivity [24] .
Using SSCA, we identified five different mutations in SLC3AJ. Figure 2 shows an autoradiograph obtained from non-denaturing gels illustrating the abnormal migration of single-strand conformers in our patients. A common abnormal single-strand conformation occurring in exon 8 was observed in nine patients. Direct sequencing of this allele demonstrated it to be a previously reported missense mutation, M467T [11] . Most of our patients with this mutation are compound heterozygotes with a second as yet undefined mutation.
We also observed three other distinct single-strand conformers in exon 8 (Fig. 2, lower (Fig. 3, top) . This nucleotide change results in the substitution of tryptophan for arginine-452 (designated as R452W), a residue conserved at this position in human, rat, and rabbit sequences. This sequence variant was not detected in any other cystinuric probands or in 97 normal control DNA samples examined by allele-specific oligonucleotide hybridization. The non-conservative nature of R452W and its absence in 194 normal chromosomes suggests that it is a mutation rather than a polymorphism. The nucleotide change responsible for R452W occurs in the context of a CpG dinucleotide (CGG), which is a known "hot spot" for mutations [25] . The abnormal SSCA conformer derived from the Swedish proband revealed a T to C transition at the nucleotide predicting the replacement of tyrosine-461 with histidine (Fig. 3, bottom) . Tyrosine is a conserved resdue at this position in human, rat and rabbit sequences. This abnormal conformer was not seen in 94 alleles from patients without the cystinuria phenotype screened by SSCA. The non-conservative nature of the Y461H substitution and its absence in 94 normal chromosomes is consistent with a mutation.
Sequencing of the abnormal exon 8 conformer found in DNA from patient 16 (lane 6) revealed a G to T transversion involving the first nucleotide of intron 8, a mutation previously reported by Horsford et al [15] . This nucleotide change alters the sequence of the splice junction at this location such that the GT dinucleotide normally present at the start of intron 8 is replaced by IT (designated as 1500 + hG -÷ T). This sequence abnormality is likely to cause aberrant splicing of pre-mRNA transcribed from the gene as inferred from the documented effect of this type of mutation in several other human genes [26] .
A fourth distinct mutation was found in exon 4 (Fig. 2) . DNA from patient 20 (lane 3, exon 4) appeared homozygous for an abnormal single-strand conformation. Sequencing of the allele revealed a previously reported nonsense mutation at codon 270 (R270X) [14] . Figure 4 illustrates the approximate locations of the mutations and splice junctions reported in this paper using a proposed transmembrane topology model experimentally derived for the SLC'3A1 gene product [271.
Discussion
Cystinuria is a common inherited disease with an estimated incidence of between 1:7000 and 1:12000 worldwide [1] . Much higher incidence rates are observed in certain ethnic populations. The disorder carries substantial morbidity associated with recurrent nephrolithiasis such as pain, urinary tract obstruction, infection, and loss of renal function. Current pharmacological therapies are directed at solubilizing cystine through disulfide exchange with D-penicillamine or other compounds along with modulating urinary volume and pH. Understanding the molecular basis for this disorder may facilitate the development of additional therapies aimed at replacing the defective gene product.
The first breakthrough in discerning the molecular genetics of cystinuria occurred in 1994 with the identification of mutations in the gene coding for a cystine transporter (SLC3A1) [11] . Since then, additional mutations have been defined providing strong evidence that SLC3A1 is indeed a cystinuria gene [12] [13] [14] . However, vast numbers of cystinuria probands exist for whom no molecular genetic data exists. Furthermore, certain allelic subsets of cystinuria as defined by cystine excretion in asymptomatic heterozygous carriers may be caused by mutations at other loci. Recent evidence indicates that type III cystinuria, characterized by intermediate levels of urinary cystine in carriers, is not linked to SLC3A], suggesting the existence of a second cystinuria locus [13] . Clearly more studies are needed to fully document the spectrum of SLC3AJ mutations and to delineate the basis for the apparent genetic heterogeneity.
We have defined the complete intron-exon organization of the SLC3AJ coding region to facilitate more rapid screening of eystinuria probands for mutations. Knowledge of the genomic organization of the gene has allowed us to develop a panel of oligonucleotide primers for PCR amplification of each exon directly from patient genomic DNA. This approach obviates the need for the time consuming and labor intensive process of establishing lymphoblastoid lines from patient lymphocytes to examine the SLC3AI sequence through use of illegitimate transcripts [11] . This should thus facilitate the systematic detection of SLC3AJ genotypes in larger populations and may be more amenable to the development of diagnostic screening assays. We report here two novel SLC3..41 mutations associated with cystinuria. Both are missense mutations in exon 8 (R452W and Y461H) located in the intracellular loop between the second and third transmembrane spanning segments according to the model proposed by Mosckovitz et al (Fig. 4) [27] . The position of these R270X mutations are close to that of two other alleles (M467T, M467K) located within the third transmembrane segment. The M467T mutation has been shown to reduce L-cystine transporter activity of recombinant rBAT by -80% when expressed in Xenopus oocytes [11] . The functional effects of M467T and the clustering of mutations in this region of the protein suggest that there are stringent structural requirements within this segment for normal transporter function.
